Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of rat prostate cancer tissue treated with OBP-801, novel HDAC inhibitor

ABSTRACT: Expression data of rat prostate cancer tissue treated with OBP-801, novel HDAC inhibitor

PROVIDER: PRJNA302226 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

miRNA expression data of rat prostate cancer tissue treated with OBP-801, novel HDAC inhibitor

Project description:miRNA expression was obtained from non-treated or OBP-801 treated TRAP rats which develop prostate cancer. The primary aim was to identify miRNAs which regulate prostate carcinogenesis induced by OBP-801.

2016-12-01 | GSE75020 | GEO

Gene expression data of rat prostate cancer tissue treated with OBP-801, novel HDAC inhibitor

Project description:Genome-wide gene expression was obtained from non-treated or OBP-801 treated TRAP rats which develop prostate cancer. The primary aim was to identify genes which regulate prostate carcinogenesis induced by OBP-801.

2016-12-01 | GSE75021 | GEO

Gene expression profiles of prostate cancer cell line with or without HDAC inihbitors

Project description:Histone deacetylase (HDAC) inibitors suppress cell proliferation of prostate cancer, but the detailed mechanisms are unknown. Moreover, HDAC includes 18 family members, namely HDAC1-11 and SIRT1-7, and differences of effects on prostate cancer proliferation among these enzymes are also unknown. Thus, we clarified differences of gene expression between prostate cancer cell line (LNCaP) treated with pan-HDAC inhibitors (TSA and OBP-801) or selective HDAC inhibitor (NCC-149, HDAC8-specific inhibitor)using cDNA microarray. LNCaP treated with TSA (1Î¼M), NCC149 (2Î¼M), OBP-801 (200nM) or DMSO for 24hrs, RNA was extracted from cells, and cDNA array was performed.

2015-11-04 | E-GEOD-74418 | biostudies-arrayexpress

Gene expression profiles of prostate cancer cell line with or without HDAC inihbitors

2015-11-04 | GSE74418 | GEO

Expression data of rat prostate cancer tissue treated with OBP-801, novel HDAC inhibitor

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-12-01 | GSE75022 | GEO

Expression data in PC3 prostate cancer cells treated with DMSO, HDAC inhibitor, EZH2 inhibitor, or combined HDAC and EZH2 inhibitors.

Project description:Expression data in PC3 prostate cancer cells treated with DMSO, HDAC inhibitor, EZH2 inhibitor, or combined HDAC and EZH2 inhibitors.

| PRJNA630152 | ENA

Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency

Project description:Rationale: Myocardial fibrosis manifests progressively in several forms of cardiomyopathies. Although fibrosis depicts a reparative mechanism, maladaptation of the heart due to excessive production of extracellular matrix accelerates cardiac dysfunction. Objective: The anthraquinone Rhein, a compound from rhubarb, was examined for its anti-fibrotic potency to mitigate cardiac fibroblast-to-myofibroblast transition (FMT). Methods and Results: Primary human ventricular cardiac fibroblasts were subjected to hypoxia and characterized with proteomics, transcriptomics and cell functional techniques. Knowledge based analyses of the omics data revealed a modulation of fibrosis-associated pathways and cell cycle due to Rhein administration, whereas p53 and p21 were identified as upstream regulators involved in the manifestation of cardiac fibroblast phenotypes. Mechanistically, Rhein-mediated cellular effects were linked to the histone deacetylase (HDAC)-dependent acetylation status of p53 a posttranslational modification that acts protein stabilizing. Direct enzymatic testing revealed an inhibitory potency of Rhein for HDAC classes I/II. Functionally, Rhein inhibited collagen contraction in response to protein abundance of SMAD7, endogenous inhibitor of TGFβ1 action, thus demonstrating its anti-fibrotic property in cardiac remodeling. Conclusion: In conclusion, this study identifies Rhein as a novel potent HDAC inhibitor and provides evidence that Rhein may contribute to the treatment of cardiac fibrosis as anti-fibrotic agent. As readily available drug with approved safety, Rhein constitutes a promising potential therapeutic approach in the supplemental and protective intervention of cardiac fibrosis.

2020-04-17 | GSE136039 | GEO

Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency

Project description:Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifibrotic potency

| PRJNA561082 | ENA

Schistosomula exposed to HDAC inhibitor (Trichostatin A)

Project description:Schistosomula exposed to HDAC inhibitor (Trichostatin A)

| PRJNA325300 | ENA

HDAC and aminopeptidase inhibitor treatment of myeloma cells

Project description:H929 human myeloma cells were exposed to aminopeptidase inhibitor (CHR-2797), HDAC inhibitor (CHR-3996), or a combinaion of the two agents, for 24 hours. Following this treatment RNA was extracted and microarrays used to determine gene expression changes. Myeloma cells were exposed to chemotherapeutic agent for 24 hours.

2014-01-24 | E-GEOD-20405 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data